Howard Rood

Experience

• 

  Abbott Molecular a Division of Abbott Laboratories

  Feb 1997 - Jan 2013

  Accountable for development and execution of the Cross Divisional Global Transplant Franchise.• Created Long Range Plan and guided recommendations to senior management for Stage Gate and Global Forecasting processes consistently resulting in meeting or exceeding year over year growth rates of 7-24%. Designed and executed all market research activities. Recent new business development deals resulted in IRR’s over 20% and Contribution Margins over 50%.• Led cross functional global teams, area buy-in, and directed new biomarker market/technology assessments in nephrology, HIV, HCV, cell mediated immunity and immune compromised diseases.• Designed/executed a Global Marketing interactive website/database designed to house all marketing materials, facilitate global collaboration and enable utilization metrics tracking.• Led business development technology, IP, strategic alliance and acquisition target due diligence.• Developed deal models for five acquisition targets ranging from $7 MM -$700 MM.• Led Pharmacogenetics initiatives focused on adverse drug reaction opportunities.• Benchmarked Best Practices and developed and presented product launch activities, competitive assessments, sales tools and Ad/Promo developments at global sales meetings, generating intra-and inter-net web metrics among the top 5% of all products in the Abbott Molecular portfolio.• Initiated and developed relationships with OEM partners and led creation of a specialized sales force to establish project parameters in alignment with business objectives, successfully expanding global market penetration to increase revenue significantly.• Managed OEM regulatory, FDA/CE Mark device submission coordination process with OEM partners.• Created and presented to senior management an antifungal and immune compromised strategy as well as a renal theragnostic technology review to twenty of the world’s top nephrologists.• Hiring, development, performance reviews, budget, and management of staff. Show less Development and launch of the m1000 systems (50% of revenue 12/10) and Transplant Strategy..• Met or exceeded all sales, marketing, financial, and performance management goals.• Designed and executed the m1000 Marketing Strategy targeted at $1Billion market opportunity.• Managed product development and marketing objectives among cross functional teams including:• R&D, Software/LIS, System Engineering, Regulatory Affairs, Finance, Quality, Legal, Operations and Global Sales and Senior Management as well as all branding and outside agency management.• Developed a transplant funding strategy, gained full support, in a cost sensitive division climate.• Co-developed a sales force P&L decision model inclusive of all Abbott Molecular Systems.• Co-developed a transplant research web tool designed to improve donor/recipient matching and enable improved research data access www.allelefrequencies.net.• Negotiated and implemented two Global Exclusive Strategic Alliance Agreement’s, led commercial due diligence for opportunities representing a transplant potential available market of over $200 MM.. Show less Responsible for all strategic and tactical strategies for the HLA Transplant Products and Next Generation Molecular Systems to ensure meeting or exceeding the sales and long range plan.• OEM strategic and tactical strategy resulting in on market inventory improving from 33% 1999 to 95% 2000, 127% WW sales growth 2000 versus 1999. Major initiatives completed: • Competitive Intelligence Assessments to identify product gaps and Next Gen Product Requirements, Long-Range Marketing and Tactical Joint Development with primary OEM partner, Development Metrics monitoring execution of a Global Transplant Regulatory Strategy, and led team through two expedited global product launches.• Designed and executed all market research, branding and agency management, and financial assessments to gain senior management and global counterparts buy-in. Show less Incremental role to current position at the timeLed cross-divisional teams in design and execution of Corporate Divisional Molecular Strategy ultimately leading to the creation of Abbott Molecular as its own Abbott Division with ~$500 MM in sales (2013).• Team leader for four of nine core venture teams. Coordinated team inputs (20 members), led reviews, creation and direction of final Molecular Business Plan, Branding Development, and CEO and Divisional President Executive Management Reviews. Show less Incremental role to current position at the time• Appointed by DVP US Marketing to lead a cross functional team to assess, analyze, and recommend the format for a replacement of the divisional customer pricing strategy.• Developed a database of all non GPO US Sales by customer and AUP and gated against all GPO contracts• Analyzed pricing trends, segmentation, integrity gaps, profitability and risk• Provided recommendations which became the initial blueprint for the new US pricing restructure Show less • Executed product marketing plans and strategies for 4 product lines representing over $250MM in base business• Developed and presented Annual PLAN and Quarterly Update’s to Sr. Divisional Management • Led a 20 member cross functional team to establish design goals, monitor project development, and launch the web and P&L based Cost Per Reportable Instrument and Reagent Pricing Strategy and Program• Initiated, designed and created novel pricing and P&L management sales tools that expedited successful launch of 3 division priorities (Cost Per Reportable (CPR), Data Management and ARCHITECT)• Developed and implemented IMx Risk Strategy and incentive plan to protect over $50MM base business• Creatively acquired external funding support of $350,000 for the CPR project when original funding was tasked• Initiated, developed, and implemented the ARCHITECT Laboratory Information System (LIS) Launch Strategy to expedite sales upside• Developed and managed competitive intelligence SWAT Teams and sales tools for primary competitors • Conducted US trade show floor and Abbott Park VIP demos• Developed and executed sales force training presentations at 1997-9 National Sales Meetings Show less

  • Global Marketing Manager Transplant Franchise

    Aug 2004 - Jan 2013

  • Global Marketing Manager

    Jul 2001 - Aug 2004

  • Global Marketing Sr Product Manager New Product Development, HLA, Next Gen Molecular Systems

    May 2000 - Jul 2001

  • Molecular Strategy Cross Divisional Venture Team Leader

    Nov 1999 - Nov 2000

  • Worldwide Marketing Senior Product Manager STD’s, Cervical Cancer, and Systems

    Jan 1999 - May 2000

  • Special Project Leader US Marketing

    Sept 1998 - Jan 1999

  • US Marketing Product Manager X Systems, Data Management, Y2K, ARCHITECT

    Feb 1997 - Jan 1999
• 

  Congregation Or Tikvah

  Jan 2009 - Jan 2012

  President
• 

  Rood Enterprises LLC - DBA FTP* Consulting

  Jun 2013 - May 2014

  President

  Develop and execute business intelligence, due diligence, and market assessments within the In-Vitro Diagnostic, Life Science, and Pharmaceutical Global Market Segments to contracted clientsWhy the name FTP Consulting (Find the Pony)?I am often asked about this. This is from a short popular joke attributed to Ronald Reagan about the eternal optimist and describes my approach to business challenges and life. I tend to dig deeper than most in the market to uncover the hidden ponies in business challenges, opportunities, and strategies and don't give up until I figure out a solution. Regardless of your political direction, it reflects a valuable life insight. Click on the document link to read the Pony Joke. http://www.mondaymorningmemo.com/got-to-be-a-pony-in-here-somewhere/ Show less

• 

  Beckman Coulter Molecular, a Danaher Company

  May 2014 - Dec 2017

  Senior Global Marketing Manager

  Global Marketing Upstream and Downstream responsibility for a novel Molecular Diagnostic Instrument System, Beckman Coulter Molecular’ largest funded strategic initiative targeting a $6.1B market and represents 4 of the top 10 2016 Danaher Corporate Priorities.Core responsibilities include Business Unit Core Team Leadership; global cross functional team development, execution, and KPI measurement of instrument, software, manufacturing operations, and assay R&D development. Typical Upstream deliverables include VOC/Design Input Marketing Requirements and ownership and leadership of Danaher-wide market research initiative and molecular diagnostics / companion diagnostics competitive intelligence monitoring. Typical Downstream deliverables include; creation/execution/KPI monitoring of upstream and downstream marketing sales training, sales collateral, and strategic/tactical tools; peer reviewed KOL publications, technical promotional materials as well as various customer facing communications. Long term strategic responsibilities include full product portfolio life cycle management planning; new assay market modeling for infectious disease, women's health, oncology, and hospital acquired infections (HAI) targets; global forecasting, P&L tool creation, reimbursement, health economic medical outcomes and human factors studies; M&A and OEM strategic alliance assessments, and developing/executing regulatory technical writing training strategies in preparation for FDA submission. Show less

• 

  PURA Ohio Processing, LLC

  Jan 2018 - now

  Board Member and Technical Consultant

  Provide organizational, marketing, market research, customer needs assessments, financial acumen, project management, operational and US FDA expertise required for product license application, manufacturing submission and State of Ohio Licensure approval. Ohio Department of Commerce Provisional License approved 1/2019. Success required collaborative tactics and balanced decision making, across numerous politically sensitive objectives. Goals achieved applying my ability to influence others across multiple entrenched silos. Partial list of deliverables completed included Value Proposition, Project Management, Project Plan, Marketing Plan, Product Life Cycle, and Policy and Procedure development Show less

• 

  Rood Enterprises LLC, dba FTP Consulting

  Feb 2018 - now

  President

  Applied personal communication skills, networking, influence and proven track record towards Consulting Company launch (2013) and relaunch (2018). Developed and executed business intelligence, due diligence, and market assessments within In-Vitro Diagnostic, Life Science, Medical Device and Pharmaceutical Global Market Segments. Projects focused on companion diagnostics, molecular diagnostics, infectious disease, oncology, neurology, novel biomarker and technology assessments, sales and product launch effectiveness, change management and administration of LEAN process improvements. Show less